Steven Gannon, Director, on August 11, 2026, sold 10,000 shares in Xenon Pharmaceuticals (XENE) for $640,550. Following the Form 4 filing with the SEC, Gannon has control over a total of 1,870 common shares of the company, with 1,870 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1582313/000119312526349351/xslF345X05/ownership.xml